Escitalopram for major depression in Parkinson's disease: An open-label, flexible-dosage study

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 18, Issue 3, 2006, Pages 377-383

  Weintraub, Daniel ^a,c   Taraborelli, Donna ^a   Morales, Knashawn H ^b   Duda, John E ^a   Katz, Ira R ^a   Stern, Matthew B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; LEVODOPA; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; CITALOPRAM;

AFFECT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MOTOR PERFORMANCE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TREATMENT RESPONSE; EMOTION; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COGNITION; DEPRESSIVE DISORDER, MAJOR; EMOTIONS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES;

EID: 85047683050     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2006.18.3.377     Document Type: Article

References (44)

1. Weintraub D: Diagnosing and treating depression in patients with Parkinson's disease. Psychiatr Ann 2004; 34:299-304
2. Richard IH, Kurlan R, Parkinson Study Group: A survey of antidepressant use in Parkinson's disease. Neurology 1997; 49:1168-1170
3. Wermuth L, Sorensen PS, Timm S, et al: Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial. Nord J Psychiatry 1998; 52:163-169
4. Leentjens AF, Vreeling FW, Luijckx GJ, et al: SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003; 18:552-554
5. Dell'Agnello G, Ceravolo R, Nuti A, et al: SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001; 24:221-227
6. Ceravolo R, Nuti A, Piccinni A, et al: Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000; 55:1216-1218
7. Hauser RA, Zesiewicz TA: Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997; 12:756-759
8. Rampello L, Chiechio S, Raffaele R, et al: The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002; 25:21-24
9. Tesei S, Antonini A, Canesi M, et al: Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000; 15:986-989
10. Menza MA, Marin H, Kaufman K, et al: Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004; 16:315-319
11. Damsa C, Bumb A, Bianchi-Demicheli F, et al: "Dopamine- dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004; 65:1064-1068
12. van de Vijver DA, Roos RA, Jansen PA, et al: Start of a selective serotonin reuptake inhibitor (SSRI) and increase of anti-parkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2003; 54:168-170
13. Menza MA, Robertson-Hoffman DE, Bonapace AS: Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34:465-470
14. Kuzis G, Sabe L, Tiberti C, et al: Cognitive functions in major depression and Parkinson's disease. Arch Neurol 1997; 54:982-986
15. Marsh L, Williams JR, Rocco M, et al: Psychiatric comorbidities in patients with Parkinson's disease and psychosis. Neurology 2004; 63:293-300
16. Starkstein SE, Mayberg HS, Preziosi TJ, et al: Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:134-139
17. Arciniegas DB, Topkoff J: The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin Clin Neuropsychiatry 2000; 5:290-306
18. Aronson S, Delgado P: Escitalopram. Drugs Today (Barc) 2004; 40:121-131
19. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56:33-39
20. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:196-198
21. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version. Washington, DC, American Psychiatric Press, 1996
22. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
23. Guy W: ECDEU Assessment Manual for Psychopharmacology-Revised, DHEW Publication number (ADM) 76-338 Ed. Rockville, Md, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976
24. Rush AJ, Gullion CM, Basco MR, et al: The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26:477-486
25. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
26. Moore SR, Gresham LS, Bromberg MB, et al: A self report measure of affective lability. J Neurol Neurosurg Psychiatry 1997; 63:89-93
27. Fahn S, Elton RL, Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale in Recent Developments in Parkinson's Disease. Edited by Fahn S, Marsden CD, Calne DB, et al. Florham Park, NJ, Macmillan Health Care Information, 1987
28. Hoehn MH, Yahr MD: Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442
29. Brandt J, Benedict RHB: The Hopkins Verbal Learning Test-Revised: Professional Manual. Odessa, Fla, Psychological Assessment Resources, 2001
30. Culbertson WC, Zillmer EA: Tower of London-Drexel (TOLDX): Technical Manual. North Tonawanda, NY, Multi-Health Systems, 2001
31. Reitan R: Validity of the Trail Making Test as an indicator of organic brain disease. Percept Psychomot Skills 1958; 8:271-276
32. Rush AJ, Giles DE, Schlesser MA, et al: The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1985; 18:65-87
33. Roose SP, Sackheim HA, Krishnan KRR, et al: Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004; 161:2050-2059
34. Arranz FJ, Ros S: Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: an open multicentre study. J Affect Disord 1997; 46:285-291
35. Newhouse PA, Krishnan KRR, Doraiswamy PM, et al: A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61:559-568
36. Mulsant BH, Pollock BG, Nebes RD, et al: A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001; 9:406-414
37. Weihs KL, Settle EC, Batey SR, et al: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61:196-202
38. Bondareff W, Alpert M, Friedhoff AJ, et al: Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157:729-736
39. Mayberg HS, Starkstein SE, Sadzot B, et al: Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990; 28:57-64
40. Brown AS, Gershon S: Dopamine and depression. J Neural Transm Gen Sect 1993; 91:75-109
41. Mayeux R, Stern Y, Cote L, et al: Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34:642-646
42. Mentis MJ, McIntosh AR, Perrine K, et al: Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 2002; 159:746-754
43. Leentjens AF: Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004; 17:120-126
44. Alexopolous GS, Lerner DM, Salzman C: Treatment of depression with tricyclic antidepressants, monoamine oxidase inhibitors, and psychostimulants, in Clinical Geriatric Psychopharmacology. Edited by Salzman C. Philadelphia, Lippincott Williams & Wilkins, 2005